SAB Biotherapeutics, Inc. filings document the regulatory record of a clinical-stage biopharmaceutical company developing SAB-142 for type 1 diabetes and other autoimmune diseases. Form 8-K disclosures cover clinical presentations, Regulation FD materials, and material agreements, including manufacturing services for SAB-142.
The company’s filings also describe its capital structure and financing activity, including common stock, pre-funded warrants, public offering agreements and shelf registration use. Proxy materials cover annual meeting matters, director elections, board composition, stockholder voting items and related governance disclosures.
SAB Biotherapeutics, Inc. reported that on January 12, 2026 it posted an updated corporate presentation on its official website. The presentation, dated January 12, 2026 and referenced as Exhibit 99.1, is intended for investors and other stakeholders seeking an overview of the company and its plans. The disclosure notes that this presentation is being furnished rather than filed under securities laws, meaning it is not automatically incorporated into other regulatory documents unless specifically referenced.
SAB Biotherapeutics, Inc. granted director Rita Jain a new equity award. On January 5, 2026, she received a stock option to purchase 240,000 shares of common stock at an exercise price of $3.74 per share. This represents her inaugural grant as a member of the company’s Board of Directors.
The option expires on January 5, 2036 and the underlying shares vest in three equal annual installments on January 5, 2027, January 5, 2028, and January 5, 2029. The award was made under SAB Biotherapeutics’ 2021 Omnibus Equity Incentive Plan, as amended, and is held directly by Jain.
SAB Biotherapeutics director David Zaccardelli received a new stock option grant. On January 5, 2026, he was awarded options to purchase 240,000 shares of SAB Biotherapeutics, Inc. common stock at an exercise price of $3.74 per share. The options expire on January 5, 2036 and were granted as his inaugural award for serving on the company’s Board of Directors.
The shares underlying this option vest in three equal annual installments on January 5, 2027, January 5, 2028, and January 5, 2029, and were issued under the company’s 2021 Omnibus Equity Incentive Plan, as amended. After this grant, he beneficially owns 240,000 derivative securities in the form of these options, held directly.
SAB Biotherapeutics, Inc. director Rita Jain filed an initial insider ownership report on Form 3 for the company’s common stock. As of the event date of 01/05/2026, the filing states that no securities of SAB Biotherapeutics are beneficially owned, and both the non-derivative and derivative securities tables show no holdings. This indicates that, while serving as a director, Jain reports no direct or indirect ownership in the company’s securities at the time of this filing.
SAB Biotherapeutics, Inc. director David Zaccardelli filed an initial beneficial ownership report on Form 3, with an event date of 01/05/2026. The filing states that no securities of SAB Biotherapeutics are beneficially owned, and both the non-derivative and derivative tables show no holdings.
SAB Biotherapeutics, Inc. reported that its board appointed David Zaccardelli, Pharm.D., and Rita Jain, M.D., as Class II directors effective January 5, 2026. They will serve until the 2026 annual meeting of stockholders or until successors are elected and qualified.
Dr. Zaccardelli has been named Chairperson of the Board, while Chief Executive Officer Samuel J. Reich steps down as chair but continues as a director. Both new directors were recommended by RA Capital Healthcare Fund, L.P. under a July 21, 2025 letter agreement related to a July 2025 private placement. They will receive compensation similar to other non-employee directors and have entered into customary indemnity agreements. On January 7, 2026, the company issued a press release announcing these appointments.
SAB Biotherapeutics, Inc. director Jay S. Skyler reported receiving a stock option grant as part of his 2025 annual compensation for serving on the board. On 12/16/2025, he was granted an option to purchase 150,000 shares of common stock at an exercise price of $3.99 per share.
The option was issued under the company’s 2021 Omnibus Equity Incentive Plan, as amended. The shares underlying this option vest in two equal annual installments on December 16, 2026 and December 16, 2027, meaning the director earns the right to exercise half the options on each of those dates if service conditions are met.
SAB Biotherapeutics, Inc. reported an equity award to director William James Polvino. On December 16, 2025, he received a stock option covering 150,000 shares of common stock at an exercise price of $3.99 per share. This grant represents his 2025 annual compensation as a member of the Board of Directors. The option vests in two equal installments on December 16, 2026 and December 16, 2027, meaning he earns the right to exercise half the option on each of those dates. The award was granted under the company’s 2021 Omnibus Equity Incentive Plan, as amended.
SAB Biotherapeutics, Inc. disclosed that a director received a new stock option grant as part of 2025 board compensation. On December 16, 2025, the director was granted a stock option to purchase 150,000 shares of common stock at an exercise price of $3.99 per share, expiring on December 16, 2035. The filing shows the director beneficially owning 150,000 derivative securities directly after this transaction.
According to the disclosure, this grant represents the director’s 2025 annual grant for board service. The shares underlying the option vest in two equal annual installments on December 16, 2026 and December 16, 2027. The award was made under the company’s 2021 Omnibus Equity Incentive Plan, as amended, which governs how equity-based compensation is issued to eligible participants.